Tomos E Walters1,2, Jonathan M Kalman1,2, Sheila K Patel3, Megan Mearns1, Elena Velkoska3, Louise M Burrell3,4. 1. Department of Cardiology, The Royal Melbourne Hospital, Melbourne, VIC, Australia. 2. Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Parkville, VIC, Australia. 3. Department of Medicine, The University of Melbourne, Austin Hospital, Heidelberg, VIC, Australia. 4. Department of Cardiology, The Austin Hospital, Melbourne, VIC, Australia.
Abstract
AIM: Angiotensin converting enzyme 2 (ACE2) is an integral membrane protein whose main action is to degrade angiotensin II. Plasma ACE2 activity is increased in various cardiovascular diseases. We aimed to determine the relationship between plasma ACE2 activity and human atrial fibrillation (AF), and in particular its relationship to left atrial (LA) structural remodelling. METHODS AND RESULTS: One hundred and three participants from a tertiary arrhythmia centre, including 58 with paroxysmal AF (PAF), 20 with persistent AF (PersAF), and 25 controls, underwent clinical evaluation, echocardiographic analysis, and measurement of plasma ACE2 activity. A subgroup of 20 participants underwent invasive LA electroanatomic mapping. Plasma ACE2 activity levels were increased in AF [control 13.3 (9.5-22.3) pmol/min/mL; PAF 16.9 (9.7-27.3) pmol/min/mL; PersAF 22.8 (13.7-33.4) pmol/min/mL, P = 0.006]. Elevated plasma ACE2 was associated with older age, male gender, hypertension and vascular disease, elevated left ventricular (LV) mass, impaired LV diastolic function and advanced atrial disease (P < 0.05 for all). Independent predictors of elevated plasma ACE2 activity were AF (P = 0.04) and vascular disease (P < 0.01). There was a significant relationship between elevated ACE2 activity and low mean LA bipolar voltage (adjusted R2 = 0.22, P = 0.03), a high proportion of complex fractionated electrograms (R2 = 0.32, P = 0.009) and a long LA activation time (R2 = 0.20, P = 0.04). CONCLUSION: Plasma ACE2 activity is elevated in human AF. Both AF and vascular disease predict elevated plasma ACE2 activity, and elevated plasma ACE2 is significantly associated with more advanced LA structural remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
AIM: Angiotensin converting enzyme 2 (ACE2) is an integral membrane protein whose main action is to degrade angiotensin II. Plasma ACE2 activity is increased in various cardiovascular diseases. We aimed to determine the relationship between plasma ACE2 activity and human atrial fibrillation (AF), and in particular its relationship to left atrial (LA) structural remodelling. METHODS AND RESULTS: One hundred and three participants from a tertiary arrhythmia centre, including 58 with paroxysmal AF (PAF), 20 with persistent AF (PersAF), and 25 controls, underwent clinical evaluation, echocardiographic analysis, and measurement of plasma ACE2 activity. A subgroup of 20 participants underwent invasive LA electroanatomic mapping. Plasma ACE2 activity levels were increased in AF [control 13.3 (9.5-22.3) pmol/min/mL; PAF 16.9 (9.7-27.3) pmol/min/mL; PersAF 22.8 (13.7-33.4) pmol/min/mL, P = 0.006]. Elevated plasma ACE2 was associated with older age, male gender, hypertension and vascular disease, elevated left ventricular (LV) mass, impaired LV diastolic function and advanced atrial disease (P < 0.05 for all). Independent predictors of elevated plasma ACE2 activity were AF (P = 0.04) and vascular disease (P < 0.01). There was a significant relationship between elevated ACE2 activity and low mean LA bipolar voltage (adjusted R2 = 0.22, P = 0.03), a high proportion of complex fractionated electrograms (R2 = 0.32, P = 0.009) and a long LA activation time (R2 = 0.20, P = 0.04). CONCLUSION: Plasma ACE2 activity is elevated in human AF. Both AF and vascular disease predict elevated plasma ACE2 activity, and elevated plasma ACE2 is significantly associated with more advanced LA structural remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Paul A Welling; Daniel Batlle; James Brian Byrd; Louise M Burrell; Andrew M South; Matthew A Sparks Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-05-01 Impact factor: 5.464
Authors: Aliza Hussain; Olive Tang; Caroline Sun; Xiaoming Jia; Elizabeth Selvin; Vijay Nambi; Aaron Folsom; Gerardo Heiss; Faiez Zannad; Thomas Mosley; Salim S Virani; Josef Coresh; Eric Boerwinkle; Bing Yu; Jonathan W Cunningham; Amil M Shah; Scott D Solomon; James A de Lemos; Ron C Hoogeveen; Christie M Ballantyne Journal: Am J Cardiol Date: 2021-02-02 Impact factor: 2.778
Authors: Ali A Rabaan; Shamsah H Al-Ahmed; Javed Muhammad; Amjad Khan; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Awad Al-Omari; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Muhammad Bilal; Salem A Alyami; Talha Bin Emran; Mohammad Ali Moni; Kuldeep Dhama Journal: Vaccines (Basel) Date: 2021-04-29
Authors: Charles D Bengtson; Robert N Montgomery; Usman Nazir; Lewis Satterwhite; Michael D Kim; Nathan C Bahr; Mario Castro; Nathalie Baumlin; Matthias Salathe Journal: Front Med (Lausanne) Date: 2021-02-17
Authors: Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos Journal: J Clin Hypertens (Greenwich) Date: 2020-09-16 Impact factor: 3.738